4/A//SEC Filing
Inscobee Inc. 4/A
Accession 0001474506-25-000109
CIK 0001894525other
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 4:36 PM ET
Size
13.4 KB
Accession
0001474506-25-000109
Insider Transaction Report
Form 4/AAmended
Inscobee Inc.
10% Owner
Transactions
- Conversion
Common Stock, par value $0.01 per share
2025-05-12$2.60/sh+44,041$114,507→ 2,099,747 total - Conversion
Common Stock, par value $0.01 per share
2025-05-12$2.60/sh+71,090$184,834→ 2,055,706 total - Conversion
Convertible Promissory Note
2025-05-12→ 0 totalExercise: $2.60→ Common Stock, par value $0.01 per share (44,041 underlying) - Conversion
Convertible Promissory Note
2025-05-12→ 0 totalExercise: $2.60→ Common Stock, par value $0.01 per share (71,090 underlying)
Footnotes (3)
- [F1]On March 21, 2022, Apimeds Pharmaceuticals US, Inc. (the "Issuer") issued to Inscobee Inc. ("Inscobee") a convertible promissory note in the principal amount of $160,000 (as amended, the "March 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the March 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of an offering of the Issuer's common stock resulting in the listing of the Issuer's common stock on the NYSE American, or other national securities exchange (a "Qualified Offering"). The March 2022 Note bears interest at an annual rate of 5%. The March 2022 Note is convertible into shares of common stock at a conversion price of $2.60 per share (the "Conversion Price"). The amount reported in Column 3 of Table II represents the original principal amount of $160,000, plus $24,833 of accrued and unpaid interest.
- [F2]On May 12, 2025, the Issuer completed a Qualified Financing and all outstanding principal and accrued and unpaid interest owed under the note converted into common stock at the Conversion Price.
- [F3]On June 3, 2022, the Issuer issued to Inscobee a convertible promissory note in the principal amount of $100,000 (as amended, the "June 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the June 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The June 2022 Note bears interest at an annual rate of 5%. The June 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $100,000, plus $14,507 of accrued and unpaid interest.
Documents
Issuer
Apimeds Pharmaceuticals US, Inc.
CIK 0001894525
Entity typeother
Related Parties
1- filerCIK 0002057997
Filing Metadata
- Form type
- 4/A
- Filed
- Jun 10, 8:00 PM ET
- Accepted
- Jun 11, 4:36 PM ET
- Size
- 13.4 KB